Pharmalot

By  Ed Silverman

Taking stock of the drug industry, from the lab to the medicine chest. Sign up for the newsletter here.

Hepatitis Drugs
Pharmalot

NIH is sued for plans to award exclusive license for CAR-T therapy to Gilead

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: WHO deals Sanofi a setback over dengue vaccine; who will buy Shire?

By Ed Silverman

GlaxoSmithKline (GSK) Vaccines
Pharmalot

Glaxo has to face lawsuit by Armenians who couldn’t decipher Avandia warnings

By Ed Silverman

Pharmalot

Pharmalittle: Shire rejects latest Takeda offer; Greek parliament ends Novartis bribery probe

By Ed Silverman

Hoarding Opioids
Pharmalot

In the throes of an opioid crisis, prescriptions fell dramatically last year

By Ed Silverman

Drug Prices
Pharmalot

U.S. spending on prescription drugs rose less than 1 percent last year

By Ed Silverman

Cancer Financial Toxicity
Pharmalot

Which drug makers are most vulnerable to a new cost-shifting maneuver?

By Ed Silverman

Pharmalot

Supreme Court weighs whether to review a whistleblower case against Gilead

By Ed Silverman

Pharmalot

Pharmalittle: Amgen migraine drug show promise; DEA moves to tighten opioid rules

By Ed Silverman

FDA Campus
Pharmalot

FDA takes how long to warn companies about plant problems?

By Ed Silverman

Pharmalot

Pharmalittle: Trump plans drug pricing speech next week; Amazon shelves plan to sell drugs to hospitals

By Ed Silverman

FDA
Pharmalot

Does an FDA about-face on an Alkermes drug signal a wider policy shift?

By Ed Silverman

Pharmalot
Pharmalot

More GOP lawmakers urge U.S. trade officials to lean on Colombia over drug approvals

By Ed Silverman

Pharmaceuticals
Pharmalot

Canadian online pharmacy fined $34 million for selling counterfeit meds, but is it a ‘slap on the wrist’?

By Ed Silverman

Pharmalot

Pharmalittle: Shire sells cancer biz as Takeda circles; FDA does about-face on Alkermes drug

By Ed Silverman

Pharmalot

Former Mallinckrodt employee alleges the ingredients in a best-selling drug are a mystery

By Ed Silverman

Drug Pricing
Pharmalot

Maryland law that punished generic price gouging is ruled unconstitutional

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Sanofi warns Canada over industry treatment; Pfizer got a big boost from the new tax law

By Ed Silverman

Pharmalot
Pharmalot

New migraine drugs may give insurers a headache

By Ed Silverman

Gilead Sciences
Pharmalot

Will this experimental hepatitis C treatment break Gilead’s grip on middle-income countries?

By Ed Silverman

Pharmalot

Pharmalittle: First trial in massive opioid litigation in March; are generic drug makers in crisis?

By Ed Silverman

Pharmalot

SEC considers civil charges against Clovis Oncology over trial data for discarded drug

By Ed Silverman

CORY BOOKER
Pharmalot

Senator lashes out at drug makers for stock buybacks, but not cutting prices

By Ed Silverman

Pharmalot

Pharmalittle: Most Americans don’t know about cancer drug shortages; Ohio moves closer to ending gag clauses

By Ed Silverman

Prescription Medicine Bottles
Pharmalot

More lawmakers question FDA over probe into Floridians importing medicines

By Ed Silverman

Cancer Chemotherapy
Pharmalot

Drug company payments appear to influence oncologists’ prescribing habits

By Ed Silverman

Pharmalot

Pharmalittle: HHS drug-pricing adviser holds conflicts; should Alzheimer’s be redefined?

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.